Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2372410
Max Phase: Preclinical
Molecular Formula: C31H43N5O7S2
Molecular Weight: 661.85
Molecule Type: Small molecule
Associated Items:
ID: ALA2372410
Max Phase: Preclinical
Molecular Formula: C31H43N5O7S2
Molecular Weight: 661.85
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H]1NC(=O)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(C)(C)SSC(C)(C)[C@@H](C(O)O)NC(=O)[C@H](Cc2ccccc2)NC1=O
Standard InChI: InChI=1S/C31H43N5O7S2/c1-17-25(38)34-22(16-18-9-7-6-8-10-18)27(40)36-24(29(42)43)31(4,5)45-44-30(2,3)23(28(41)33-17)35-26(39)21(32)15-19-11-13-20(37)14-12-19/h6-14,17,21-24,29,37,42-43H,15-16,32H2,1-5H3,(H,33,41)(H,34,38)(H,35,39)(H,36,40)/t17-,21-,22-,23+,24+/m0/s1
Standard InChI Key: RUNRDTYBZFTQFP-QCIOSCQESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 661.85 | Molecular Weight (Monoisotopic): 661.2604 | AlogP: 0.73 | #Rotatable Bonds: 7 |
Polar Surface Area: 203.11 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.48 | CX Basic pKa: 7.73 | CX LogP: 0.99 | CX LogD: 0.63 |
Aromatic Rings: 2 | Heavy Atoms: 45 | QED Weighted: 0.15 | Np Likeness Score: 1.04 |
1. Sablin SO, Krueger MJ, Singer TP, Bachurin SO, Khare AB, Efange SM, Tkachenko SE.. (1994) Interaction of tetrahydrostilbazoles with monoamine oxidase A and B., 37 (1): [PMID:8289189] [10.1021/jm00027a019] |
2. Haaseth RC, Horan PJ, Bilsky EJ, Davis P, Zalewska T, Slaninova J, Yamamura HI, Weber SJ, Davis TP, Porreca F.. (1994) [L-Ala3]DPDPE: a new enkephalin analog with a unique opioid receptor activity profile. Further evidence of delta-opioid receptor multiplicity., 37 (11): [PMID:8201592] [10.1021/jm00037a007] |
3. Efange SM, Michelson RH, Remmel RP, Boudreau RJ, Dutta AK, Freshler A.. (1990) Flexible N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogues: synthesis and monoamine oxidase catalyzed bioactivation., 33 (12): [PMID:2258899] [10.1021/jm00174a007] |
4. Mabic S, Castagnoli N.. (1996) Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine., 39 (19): [PMID:8809158] [10.1021/jm9603882] |
5. Kalgutkar AS, Castagnoli N.. (1992) Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors., 35 (22): [PMID:1433219] [10.1021/jm00100a023] |
Source(1):